What's Happening?
GSK has received FDA approval for Jideytro, a drug developed as part of its $10.6 billion acquisition of Nuvalent. Jideytro is a ROS1 inhibitor designed to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)
who have previously been treated with other drugs in the same class. The drug targets tumors with resistance mutations, which have reduced the effectiveness of existing treatments like Pfizer's Xalkori and Roche's Rozlytrek. The approval follows the phase 1/2 ARROS-1 trial, where Jideytro showed a 44% objective response rate, with 69% of patients maintaining their response after 12 months. This marks GSK's first lung cancer therapy, with plans to launch the product soon.
Why It's Important?
The approval of Jideytro is significant as it addresses a critical need for effective treatments for ROS1-positive NSCLC, particularly in cases where resistance mutations have developed. This advancement could potentially improve outcomes for patients who have limited options due to resistance to existing therapies. For GSK, this approval is a strategic milestone, enhancing its oncology portfolio and potentially driving significant revenue growth. Analysts predict that Jideytro, along with other drugs acquired from Nuvalent, could generate substantial sales, contributing to GSK's goal of increasing its annual revenues significantly by 2031.
What's Next?
GSK plans to launch Jideytro in the coming weeks, although pricing details have not been disclosed. The company is also awaiting FDA decisions on other lung cancer therapies acquired from Nuvalent, including an ALK inhibitor and a HER2-altered NSCLC treatment. These developments could further strengthen GSK's position in the oncology market. Additionally, GSK is advancing another lung cancer candidate, a B7-H3-targeted antibody-drug conjugate, which recently showed positive results in a phase 3 trial for relapsed small-cell lung cancer.
